Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine and Cognitive Rehabilitation in Post-Stroke Patients
NCT01508494Phase 2Completed
- Sponsor
- Inserm
- Start
- Jun 2011
- Primary completion
- Jun 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of galantamine in stroke, cognitive impairment, sponsored by Inserm. Started Jun 2011; status: completed.
02
Drugs
galantamine
03
Conditions
strokecognitive impairment
Beyond the preview
Go deeper on NCT01508494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508494.